Skip to main
ELAN
ELAN logo

ELAN Stock Forecast & Price Target

ELAN Analyst Ratings

Based on 8 analyst ratings
Buy
Strong Buy 25%
Buy 50%
Hold 25%
Sell 0%
Strong Sell 0%

Bulls say

Elanco Animal Health has demonstrated strong market leadership in its companion animal products, with Simparica Trio maintaining over a 50% market share, while the projected increase for Credelio Quattro's market share to 16.8% by 2026 reflects significant growth potential. The Advantage Family and Seresto product lines have also shown impressive year-over-year growth of 33% and 28%, respectively, as of the third quarter of 2025, indicating robust demand and consistent performance. These trends suggest a positive trajectory for Elanco's sales and market presence, supporting an optimistic outlook for the company's financial health.

Bears say

Elanco Animal Health has raised concerns regarding its refinancing efforts, particularly in light of high interest rates exemplified by Dentsply Sirona's recent $550 million offering at 8.375%, potentially impacting earnings growth in 2026. Additionally, while the company's revenue has increased by approximately 50%, its EBITDA margin has declined by a couple of hundred basis points, indicating potential issues with profitability. Although the company reported a $28 million EBITDA outperformance in the second quarter, the combination of refinancing risks and margin compression poses significant challenges for Elanco's financial outlook.

ELAN has been analyzed by 8 analysts, with a consensus rating of Buy. 25% of analysts recommend a Strong Buy, 50% recommend Buy, 25% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Elanco Animal Health Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Elanco Animal Health Inc (ELAN) Forecast

Analysts have given ELAN a Buy based on their latest research and market trends.

According to 8 analysts, ELAN has a Buy consensus rating as of Nov 25, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $21.12, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $21.12, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Elanco Animal Health Inc (ELAN)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.